Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Alan Barge"'
Autor:
Axel Kleespies, Gudrun Köhl, Michael Friedrich, Anderson J. Ryan, Alan Barge, Karl-Walter Jauch, Christiane J. Bruns
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 7, Iss 10, Pp 957-966 (2005)
ZD6126 is a novel vascular-targeting agent that acts by disrupting the tubulin cytoskeleton of an immature tumor endothelium, leading to an occlusion of tumor blood vessels and a subsequent tumor necrosis. We wanted to evaluate ZD6126 in primary and
Externí odkaz:
https://doaj.org/article/c82c0203142f4da0a62ad693c296856c
Autor:
James R. Whittle, Lilian Chow, Adam Cooper, Aflah Roohullah, Mark McHale, Ben Tran, Paul de Souza, Anna Lomax, Lisa G. Horvath, Jayesh Desai, Jennifer Aung, Alan Barge
Publikováno v:
Investigational New Drugs. 36:886-894
Background The MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF) also known as scatter factor, are associated with tumourigenesis and metastasis by promotion of scattering, proliferation, angiogenesis, motility and invasion. ASLAN-00
Autor:
Zachary DelProposto, Antoinette J. Wozniak, Scott A. Boerner, Shirish M. Gadgeel, Helen Jones, Jeffrey Evelhoch, Pamela DeLuca, Alan Barge, Catherine Wheeler, Patricia LoRusso
Publikováno v:
Investigational New Drugs. 26:159-167
Background ZD6126 is a novel vascular-targeting agent that disrupts the endothelial tubulin cytoskeleton causing selective occlusion of tumor vasculature and extensive tumor necrosis. This Phase I clinical study was conducted to evaluate the dose and
Publikováno v:
Contemporary Clinical Trials. 28:146-152
The traditional development paradigm for phase II trials in oncology has been challenged in recent years by the introduction of cytostatic therapies. These agents slow the growth of tumors rather than cause high rates of shrinkage, this argues for th
Autor:
Anderson J. Ryan, Karl-Walter Jauch, Christiane J. Bruns, Gudrun Köhl, Axel Kleespies, Alan Barge, Michael Friedrich
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 7, Iss 10, Pp 957-966 (2005)
ZD6126 is a novel vascular-targeting agent that acts by disrupting the tubulin cytoskeleton of an immature tumor endothelium, leading to an occlusion of tumor blood vessels and a subsequent tumor necrosis. We wanted to evaluate ZD6126 in primary and
Autor:
Dieter Hoelzer, Caroline O’Brien-Ewen, Hervé Dombret, Klaus Lechner, Gerhard Heil, Eric Archimbaud, Miguel A. Sanz, Alan Barge, John A. Liu Yin, Oliver G. Ottmann, J Matcham, Wolfram Brugger, Pierre Fenaux
Publikováno v:
Blood
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Europe PubMed Central
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Europe PubMed Central
To determine the safety, biologic, and clinical benefits of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF; Amgen, Thousand Oaks, CA) after myelosuppressive chemotherapy in acute myeloid leukemia (AML),108 adult
Autor:
Paul Knöbl, Ilse Schwarzinger, Klaus Geissler, Eva Kabrna, Klaus Lechner, Alan Barge, Peter Valent, S. Eichinger, Susanna Stengg
Publikováno v:
British Journal of Haematology. 102:535-543
By participating in a randomized safety and efficacy study of pegylated-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) post induction and consolidation chemotherapy for de novo acute myeloid leukaemia, serial determinatio
Autor:
Klaus Lechner, Jeff Szer, Caroline O'Brien, Giuseppe Papa, Gerhard Heil, Luc Noens, Miguel A. Sanz, Dieter Hoelzer, Alan Barge, J Matcham, Arnold Ganser, John A. Liu Yin
Publikováno v:
Scopus-Elsevier
The safety and efficacy of filgrastim as an adjunct to acute myeloid leukemia (AML) induction and consolidation therapy was assessed in this prospective double-blind, randomized, placebo-controlled, multicenter trial. A total of 521 consecutive de no
Autor:
Anderson J. Ryan, Alan Barge
Publikováno v:
Tumor Angiogenesis ISBN: 9783540331766
Vandetanib ( ZACTIMA™; ZD6474) is a once-daily, orally available agent with potential for use in a number of solid tumour types. Vandetanib targets key signalling pathways in cancer by inhibiting vascular endothelial growth factor receptor (VEGFR)-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7de834d6afb2221a87b65bd6f0c52de7
https://doi.org/10.1007/978-3-540-33177-3_41
https://doi.org/10.1007/978-3-540-33177-3_41
Autor:
Ivan Ischenko, Alan Barge, M. Yezhelyev, Claudius Conrad, Karl-Walter Jauch, Christiane J. Bruns, Anderson J. Ryan, Stephen R. Wedge, Markus Guba, Edward K. Geissler, Gudrun Köhl, Ulrich Wiegand
Publikováno v:
Anti-cancer drugs. 18(5)
ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor receptor kinase insert domain receptor/flk-1 tyrosine kinase activity with additional activity against the epidermal growth factor receptor-1 tyrosine kinase. The aim